Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells

Vineela Chukkapalli, Leo I. Gordon, Parameswaran Venugopal, Jeffrey A. Borgia, Reem Karmali*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells'. Together they form a unique fingerprint.

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science